Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank Disease ID
1 Chagas disease 💬
 [1] CD3E 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
2 Chagas disease 💬
 [1] CD3E 💬 Cevostamab 💬 Cevostamab [1] 49 💬
3 Chagas disease 💬
 [1] CD3E 💬 Elranatamab 💬 Elranatamab [1] 28 💬
4 Chagas disease 💬
 [1] CD3E 💬 Etentamig 💬 Etentamig [1] 28 💬
5 Chagas disease 💬
 [1] CD3E 💬 Imvotamab 💬 Imvotamab [2] 46, 49 💬
6 Chagas disease 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
7 Chagas disease 💬
 [1] CD3E 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
8 Chagas disease 💬
 [1] CD3E 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
9 Chagas disease 💬
 [1] CD3E 💬 Plamotamab 💬 Plamotamab [1] 46 💬
10 Chagas disease 💬
 [1] CD3E 💬 Talquetamab 💬 Talquetamab [2] 11, 28 💬
11 Chagas disease 💬
 [1] CD3E 💬 Teclistamab 💬 Teclistamab [5] 28, 49, 50, 51, 53 💬
12 Chagas disease 💬
 [1] CD3E 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
13 Epstein-Barr virus infection 💬
 [1] CD3E 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
14 Epstein-Barr virus infection 💬
 [1] CD3E 💬 Cevostamab 💬 Cevostamab [1] 49 💬
15 Epstein-Barr virus infection 💬
 [1] CD3E 💬 Elranatamab 💬 Elranatamab [1] 28 💬
16 Epstein-Barr virus infection 💬
 [1] CD3E 💬 Etentamig 💬 Etentamig [1] 28 💬
17 Epstein-Barr virus infection 💬
 [1] CD3E 💬 Imvotamab 💬 Imvotamab [2] 46, 49 💬
18 Epstein-Barr virus infection 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
19 Epstein-Barr virus infection 💬
 [1] CD3E 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
20 Epstein-Barr virus infection 💬
 [1] CD3E 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
21 Epstein-Barr virus infection 💬
 [1] CD3E 💬 Plamotamab 💬 Plamotamab [1] 46 💬
22 Epstein-Barr virus infection 💬
 [1] CD3E 💬 Talquetamab 💬 Talquetamab [2] 11, 28 💬
23 Epstein-Barr virus infection 💬
 [1] CD3E 💬 Teclistamab 💬 Teclistamab [5] 28, 49, 50, 51, 53 💬
24 Epstein-Barr virus infection 💬
 [1] CD3E 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
25 Hematopoietic cell lineage 💬
 [1] CD3E 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
26 Hematopoietic cell lineage 💬
 [1] CD3E 💬 Cevostamab 💬 Cevostamab [1] 49 💬
27 Hematopoietic cell lineage 💬
 [1] CD3E 💬 Elranatamab 💬 Elranatamab [1] 28 💬
28 Hematopoietic cell lineage 💬
 [1] CD3E 💬 Etentamig 💬 Etentamig [1] 28 💬
29 Hematopoietic cell lineage 💬
 [1] CD3E 💬 Imvotamab 💬 Imvotamab [2] 46, 49 💬
30 Hematopoietic cell lineage 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
31 Hematopoietic cell lineage 💬
 [1] CD3E 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
32 Hematopoietic cell lineage 💬
 [1] CD3E 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
33 Hematopoietic cell lineage 💬
 [1] CD3E 💬 Plamotamab 💬 Plamotamab [1] 46 💬
34 Hematopoietic cell lineage 💬
 [1] CD3E 💬 Talquetamab 💬 Talquetamab [2] 11, 28 💬
35 Hematopoietic cell lineage 💬
 [1] CD3E 💬 Teclistamab 💬 Teclistamab [5] 28, 49, 50, 51, 53 💬
36 Hematopoietic cell lineage 💬
 [1] CD3E 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
37 Human immunodeficiency virus 1 infection 💬
 [1] CD3E 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
38 Human immunodeficiency virus 1 infection 💬
 [1] CD3E 💬 Cevostamab 💬 Cevostamab [1] 49 💬
39 Human immunodeficiency virus 1 infection 💬
 [1] CD3E 💬 Elranatamab 💬 Elranatamab [1] 28 💬
40 Human immunodeficiency virus 1 infection 💬
 [1] CD3E 💬 Etentamig 💬 Etentamig [1] 28 💬
41 Human immunodeficiency virus 1 infection 💬
 [1] CD3E 💬 Imvotamab 💬 Imvotamab [2] 46, 49 💬
42 Human immunodeficiency virus 1 infection 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
43 Human immunodeficiency virus 1 infection 💬
 [1] CD3E 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
44 Human immunodeficiency virus 1 infection 💬
 [1] CD3E 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
45 Human immunodeficiency virus 1 infection 💬
 [1] CD3E 💬 Plamotamab 💬 Plamotamab [1] 46 💬
46 Human immunodeficiency virus 1 infection 💬
 [1] CD3E 💬 Talquetamab 💬 Talquetamab [2] 11, 28 💬
47 Human immunodeficiency virus 1 infection 💬
 [1] CD3E 💬 Teclistamab 💬 Teclistamab [5] 28, 49, 50, 51, 53 💬
48 Human immunodeficiency virus 1 infection 💬
 [1] CD3E 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
49 Human T-cell leukemia virus 1 infection 💬
 [1] CD3E 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
50 Human T-cell leukemia virus 1 infection 💬
 [1] CD3E 💬 Cevostamab 💬 Cevostamab [1] 49 💬
51 Human T-cell leukemia virus 1 infection 💬
 [1] CD3E 💬 Elranatamab 💬 Elranatamab [1] 28 💬
52 Human T-cell leukemia virus 1 infection 💬
 [1] CD3E 💬 Etentamig 💬 Etentamig [1] 28 💬
53 Human T-cell leukemia virus 1 infection 💬
 [1] CD3E 💬 Imvotamab 💬 Imvotamab [2] 46, 49 💬
54 Human T-cell leukemia virus 1 infection 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
55 Human T-cell leukemia virus 1 infection 💬
 [1] CD3E 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
56 Human T-cell leukemia virus 1 infection 💬
 [1] CD3E 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
57 Human T-cell leukemia virus 1 infection 💬
 [1] CD3E 💬 Plamotamab 💬 Plamotamab [1] 46 💬
58 Human T-cell leukemia virus 1 infection 💬
 [1] CD3E 💬 Talquetamab 💬 Talquetamab [2] 11, 28 💬
59 Human T-cell leukemia virus 1 infection 💬
 [1] CD3E 💬 Teclistamab 💬 Teclistamab [5] 28, 49, 50, 51, 53 💬
60 Human T-cell leukemia virus 1 infection 💬
 [1] CD3E 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
61 Measles 💬
 [1] CD3E 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
62 Measles 💬
 [1] CD3E 💬 Cevostamab 💬 Cevostamab [1] 49 💬
63 Measles 💬
 [1] CD3E 💬 Elranatamab 💬 Elranatamab [1] 28 💬
64 Measles 💬
 [1] CD3E 💬 Etentamig 💬 Etentamig [1] 28 💬
65 Measles 💬
 [1] CD3E 💬 Imvotamab 💬 Imvotamab [2] 46, 49 💬
66 Measles 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
67 Measles 💬
 [1] CD3E 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
68 Measles 💬
 [1] CD3E 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
69 Measles 💬
 [1] CD3E 💬 Plamotamab 💬 Plamotamab [1] 46 💬
70 Measles 💬
 [1] CD3E 💬 Talquetamab 💬 Talquetamab [2] 11, 28 💬
71 Measles 💬
 [1] CD3E 💬 Teclistamab 💬 Teclistamab [5] 28, 49, 50, 51, 53 💬
72 Measles 💬
 [1] CD3E 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
73 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] CD3E 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
74 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] CD3E 💬 Cevostamab 💬 Cevostamab [1] 49 💬
75 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] CD3E 💬 Elranatamab 💬 Elranatamab [1] 28 💬
76 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] CD3E 💬 Etentamig 💬 Etentamig [1] 28 💬
77 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] CD3E 💬 Imvotamab 💬 Imvotamab [2] 46, 49 💬
78 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
79 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] CD3E 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
80 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] CD3E 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
81 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] CD3E 💬 Plamotamab 💬 Plamotamab [1] 46 💬
82 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] CD3E 💬 Talquetamab 💬 Talquetamab [2] 11, 28 💬
83 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] CD3E 💬 Teclistamab 💬 Teclistamab [5] 28, 49, 50, 51, 53 💬
84 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] CD3E 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
85 Primary immunodeficiency 💬
 [1] CD3E 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
86 Primary immunodeficiency 💬
 [1] CD3E 💬 Cevostamab 💬 Cevostamab [1] 49 💬
87 Primary immunodeficiency 💬
 [1] CD3E 💬 Elranatamab 💬 Elranatamab [1] 28 💬
88 Primary immunodeficiency 💬
 [1] CD3E 💬 Etentamig 💬 Etentamig [1] 28 💬
89 Primary immunodeficiency 💬
 [1] CD3E 💬 Imvotamab 💬 Imvotamab [2] 46, 49 💬
90 Primary immunodeficiency 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
91 Primary immunodeficiency 💬
 [1] CD3E 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
92 Primary immunodeficiency 💬
 [1] CD3E 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
93 Primary immunodeficiency 💬
 [1] CD3E 💬 Plamotamab 💬 Plamotamab [1] 46 💬
94 Primary immunodeficiency 💬
 [1] CD3E 💬 Talquetamab 💬 Talquetamab [2] 11, 28 💬
95 Primary immunodeficiency 💬
 [1] CD3E 💬 Teclistamab 💬 Teclistamab [5] 28, 49, 50, 51, 53 💬
96 Primary immunodeficiency 💬
 [1] CD3E 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
97 T cell receptor signaling pathway 💬
 [1] CD3E 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
98 T cell receptor signaling pathway 💬
 [1] CD3E 💬 Cevostamab 💬 Cevostamab [1] 49 💬
99 T cell receptor signaling pathway 💬
 [1] CD3E 💬 Elranatamab 💬 Elranatamab [1] 28 💬
100 T cell receptor signaling pathway 💬
 [1] CD3E 💬 Etentamig 💬 Etentamig [1] 28 💬
101 T cell receptor signaling pathway 💬
 [1] CD3E 💬 Imvotamab 💬 Imvotamab [2] 46, 49 💬
102 T cell receptor signaling pathway 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
103 T cell receptor signaling pathway 💬
 [1] CD3E 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
104 T cell receptor signaling pathway 💬
 [1] CD3E 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
105 T cell receptor signaling pathway 💬
 [1] CD3E 💬 Plamotamab 💬 Plamotamab [1] 46 💬
106 T cell receptor signaling pathway 💬
 [1] CD3E 💬 Talquetamab 💬 Talquetamab [2] 11, 28 💬
107 T cell receptor signaling pathway 💬
 [1] CD3E 💬 Teclistamab 💬 Teclistamab [5] 28, 49, 50, 51, 53 💬
108 T cell receptor signaling pathway 💬
 [1] CD3E 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
109 Th1 and Th2 cell differentiation 💬
 [1] CD3E 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
110 Th1 and Th2 cell differentiation 💬
 [1] CD3E 💬 Cevostamab 💬 Cevostamab [1] 49 💬
111 Th1 and Th2 cell differentiation 💬
 [1] CD3E 💬 Elranatamab 💬 Elranatamab [1] 28 💬
112 Th1 and Th2 cell differentiation 💬
 [1] CD3E 💬 Etentamig 💬 Etentamig [1] 28 💬
113 Th1 and Th2 cell differentiation 💬
 [1] CD3E 💬 Imvotamab 💬 Imvotamab [2] 46, 49 💬
114 Th1 and Th2 cell differentiation 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
115 Th1 and Th2 cell differentiation 💬
 [1] CD3E 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
116 Th1 and Th2 cell differentiation 💬
 [1] CD3E 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
117 Th1 and Th2 cell differentiation 💬
 [1] CD3E 💬 Plamotamab 💬 Plamotamab [1] 46 💬
118 Th1 and Th2 cell differentiation 💬
 [1] CD3E 💬 Talquetamab 💬 Talquetamab [2] 11, 28 💬
119 Th1 and Th2 cell differentiation 💬
 [1] CD3E 💬 Teclistamab 💬 Teclistamab [5] 28, 49, 50, 51, 53 💬
120 Th1 and Th2 cell differentiation 💬
 [1] CD3E 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬
121 Th17 cell differentiation 💬
 [1] CD3E 💬 Blinatumomab 💬 Blinatumomab [4] 11, 46, 49, 222 💬
122 Th17 cell differentiation 💬
 [1] CD3E 💬 Cevostamab 💬 Cevostamab [1] 49 💬
123 Th17 cell differentiation 💬
 [1] CD3E 💬 Elranatamab 💬 Elranatamab [1] 28 💬
124 Th17 cell differentiation 💬
 [1] CD3E 💬 Etentamig 💬 Etentamig [1] 28 💬
125 Th17 cell differentiation 💬
 [1] CD3E 💬 Imvotamab 💬 Imvotamab [2] 46, 49 💬
126 Th17 cell differentiation 💬
 [1] CD3E 💬 Mosunetuzumab 💬 Mosunetuzumab [1] 49 💬
127 Th17 cell differentiation 💬
 [1] CD3E 💬 Muromonab-CD3 💬 Muromonab [1] 60 💬
128 Th17 cell differentiation 💬
 [1] CD3E 💬 Otelixizumab 💬 Otelixizumab [1] 46 💬
129 Th17 cell differentiation 💬
 [1] CD3E 💬 Plamotamab 💬 Plamotamab [1] 46 💬
130 Th17 cell differentiation 💬
 [1] CD3E 💬 Talquetamab 💬 Talquetamab [2] 11, 28 💬
131 Th17 cell differentiation 💬
 [1] CD3E 💬 Teclistamab 💬 Teclistamab [5] 28, 49, 50, 51, 53 💬
132 Th17 cell differentiation 💬
 [1] CD3E 💬 Visilizumab 💬 Visilizumab [2] 96, 97 💬

Back to top